—各奖项申报陆续启动,欢迎关注—4月29日,信达生物交出成立十余年来的最好业绩:总收入创下历史新高,并且首次实现Non-IFRS下的净利润和EBITDA双转正。具体来说,2024年,信达生物实现总收入94.22亿元,同比增长51.8%,其中产品收入82.28亿元,同比增长43.6%;毛利79.12亿元,同比增长56.1%;年内亏损大幅收窄90%至9,463万元。而在Non-IFRS口径下,信达生物...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.